Fractional flow reserve

Haemonetics Corporation Completes Acquisition of OpSens Inc.

Retrieved on: 
Tuesday, December 12, 2023
TAVR, EBITDA, FFR, Pressure, Acquisition, NYSE, OTCQX, Fractional flow reserve, Toronto Stock Exchange, CAD, Patient, Workflow, Coronary artery disease, GAAP, Diagnosis, Growth, Physician, Hospital, DPR, Medical imaging, Haemonetics

"Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Chris Simon, Haemonetics' President and Chief Executive Officer.

Key Points: 
  • "Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Chris Simon, Haemonetics' President and Chief Executive Officer.
  • "We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world."
  • Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million draw under its revolving credit facility.
  • Following this acquisition, Haemonetics estimates that its net debt to EBITDA ratio, as defined in Haemonetics' existing credit agreement, will be approximately 2.3x.

Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

Retrieved on: 
Tuesday, October 10, 2023
Pressure, Diagnosis, Hospital, Physician, NYSE, TSX, Acquisition, FFR, Model Business Corporation Act, Piper, Fractional flow reserve, EBITDA, PCI, HVS Global Hospitality Services, TAVR, DLA, DPR, Workflow, Credit agreements in South Africa, DLA Piper, CAD, Growth, Goldman Sachs, Vascular closure device, GAAP, Patient, Coronary artery disease, Pharmaceutical industry, Medical imaging, Fine chemical, Bank, Haemonetics

BOSTON, Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.

Key Points: 
  • OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications.
  • Stewart Strong, President, Global Hospital at Haemonetics, said, "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification.
  • Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x.
  • Haemonetics posted supplemental slides with additional information about this transaction to Haemonetics' investor relations website.

SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue™ Imaging System

Retrieved on: 
Tuesday, September 19, 2023
Technology, Medical Devices, Medical Supplies, FDA, Health Technology, Cardiology, Hardware, Health, Artificial Intelligence, Plaque, Blood vessel, Myocardial infarction, EEL, Fractional flow reserve, Food and Drug Administration, NIRS, CAD, Nasiriyah Heart Center, Intelligence, Multimedia, Angiography, Meta-analysis, Calcium, Congress, Acquisition, Patient, Physician, Risk, Algorithm, Artificial intelligence, St. Francis Hospital, Coronary artery disease, European Society of Cardiology, Arrest, Food, Medical imaging

The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.

Key Points: 
  • The intravascular imaging system combines next-generation DeepOCT™ images and near infrared spectroscopy (NIRS) with state-of-the-art ease of use to support physicians optimizing coronary stenting in the cardiac catheterization lab.
  • Newly cleared product enhancements include contrast-free saline imaging, artificial intelligence algorithms to support the identification of key clinical structures of calcium and external elastic lamina (EEL), and hands-free angiographic co-registration.
  • The latest clearance adds to the existing HyperVue toolkit , which includes artificial intelligence enabled lipid, lumen, stent, and sidebranch detection, as well as the no-flush prep Starlight™ Imaging Catheter designed for efficient setup and image acquisition in complex lesions.
  • Next generation DeepOCT and Near Infrared Spectroscopy intravascular imaging system now includes compatibility with contrast-free saline imaging, advanced artificial intelligence algorithms to identify calcium and external elastic lamina, and hands-free angiographic co-registration.

Recent Study from England’s National Health Service Highlights Positive Impact of Implementing HeartFlow’s FFRCT Analysis for Diagnosis of Coronary Artery Disease

Retrieved on: 
Saturday, August 26, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Liverpool Heart and Chest Hospital, Percutaneous coronary intervention, Rare Diseases Clinical Research Network, National Health Service, FISH, NHS England, Non-fatal offences against the person in English law, CV, MI, Fractional flow reserve, Principal investigator, Cardiovascular disease, CAD, CRN, CCTA, MRC, European Society of Cardiology, PCI, Congress, Patient, Physician, Risk, CHIPS, Diagnosis, Mortality, ICA, NHS, Coronary artery disease, ESC, Medical device, Medical imaging, Pharmaceutical industry

The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.

Key Points: 
  • The FISH&CHIPS study was designed to assess at a national level the incremental impact of adding HeartFlow FFRCT to a CCTA-first (Coronary Computed Tomography Angiography) diagnostic pathway to evaluate and manage CAD.
  • FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:
    A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.
  • An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).
  • High prognostic value for FFRCT whereby patients with severely abnormal FFRCT values (≤0.50) had a 2x risk of all-cause death and a 3x risk of non-fatal MI compared to patients with normal FFRCT values.

Outlook on the Fractional Flow Reserve Global Market to 2027 - AI & ML Revolutionizing FFR-CT - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, Cardiology, CAD, First Nations in Ontario, Patient, Ageing, IHD, FFR, Adult, Probability, United Nations, Adoption, Death, Population, Urbanization, Boston Scientific, Obesity, Cardiovascular disease, Philips, Gross domestic product, Metabolic syndrome, Chest pain, Fractional flow reserve, Degenerative disease, Machine learning, GDP, Incidence, AI, Artificial intelligence, Coronary artery disease, Oil, Pharmaceutical industry, Medical imaging, Medical device, Developing country

The "Fractional Flow Reserve Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fractional Flow Reserve Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The fractional flow reserve (FFR) is a gold standard for assessing coronary artery disease during invasive coronary angiography.
  • The usage of non-invasive fractional flow reserve systems is increasing due to innovative methods in healthcare systems.
  • This increasing target population globally will drive the global fractional flow reserve market growth.

Stanford Health Care Selects HeartVista’s MRI Automation Platform to Deliver Rapid, AI-Powered Cardiac Scans

Retrieved on: 
Wednesday, January 19, 2022
Cardiology, Software, Radiology, Biotechnology, Health, Medical Devices, Hospitals, Technology, Research, Technology, GE Healthcare, International Society, Cardiology, Magnetic resonance, Adoption, Machine learning, Solution, International Society for Magnetic Resonance in Medicine, Health, National Institute, Stanford University Medical Center, Time, Intelligence, Khosla Ventures, Cardiovascular disease, Fractional flow reserve, The New England Journal of Medicine, FFR, CMR, MRI, AI, Chest pain, Hospital, Physician, Siemens Healthineers, Acquisition, Medical imaging, Medicine

The initial three-year agreement will enable Stanford Health Care to grow their cardiac MRI practice with on-site customer support and training provided by HeartVista.

Key Points: 
  • The initial three-year agreement will enable Stanford Health Care to grow their cardiac MRI practice with on-site customer support and training provided by HeartVista.
  • The AI-enabled MRI technology will be used by the health systems radiology and cardiology departments.
  • We believe that by providing cardiovascular centers of excellence like Stanford Health Care with our One-Click cardiac package, we can provide physicians with improved cardiac MRI studies, while also reducing the burden to the system and technologists.
  • The agreement between Stanford Health Care and HeartVista went into effect on January 1, 2022, and following staff training and scheduling, patient scans are to commence later this month.

OpSens Announces FIRST Quarter fiscal 2022 Financial Results

Retrieved on: 
Thursday, January 13, 2022
Consolidated, Income, Q1, TAVR, Adoption, Coronary artery disease, Health Canada, Government, Industry, Conference call, Fractional flow reserve, Aortic valve, Company, TSX, FDA, COVID, Medical device, Fossil fuel, Pharmaceutical industry, Animal, Lithium, Mobile phone, Conference

ET

Key Points: 
  • ET
    QUEBEC, Jan. 13, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens"or the "Company") (TSX: OPS)(OTCQX: OPSSF),a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology,today reported its results for the first quarter of fiscal year 2022 ended November 30, 2021.
  • Consolidated sales of $8.1 million in Q1 2022, a decrease of 3%, compared with $8.3 million in Q1 2021.
  • Industrial sales were at $0.7 million in Q1 2022 compare with $1.0 million in Q1 2021.
  • Net loss was $2.1 million in Q1 2022 compared to a net income of $0.6 million in Q1 2021.

OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results

Retrieved on: 
Tuesday, November 23, 2021
TAVR, Government, EMEA, Regulation of tobacco by the U.S. Food and Drug Administration, CEO, Aortic valve, Technology, Income, Company, Coronary artery disease, Diagnosis, Partnership, Pablo Picasso, TSX, TAVI, Fractional flow reserve, COVID-19, GPO, Conference call, Marketing, FDA, DPR, Solution, Growth, FFR, Food, Animal, Pharmaceutical industry, Airline, Cryptocurrency, Self storage

ET

Key Points: 
  • ET
    QUEBEC CITY, Nov. 23, 2021 /CNW Telbec/ -OpSens Inc. ("OpSens"or the "Company") (TSX: OPS)(OTCQX: OPSSF),a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology,today reported its results for the fourth quarter and fiscal year 2021 ended August 31, 2021.
  • Fiscal Year Financial Results - Year Ended August 31, 2021
    Total revenue was $34.5 million in FY 2021 compared with $29.5 million in FY 2020 an increase of $5 million or 17%.
  • Fourth Quarter Financial Results Three-Month Period Ended August 31, 2021
    Total revenue was $8.1 million in the Q4 2021 compared with $7.6 million in Q4 2020 an increase of $0.5 million or 7%.
  • Net loss was $1.2 million during Q4 2021 compared with a net income of $0.6 million in Q4 2020.

HeartFlow Announces Enrollment of First Three Patients in FUSION Trial

Retrieved on: 
Thursday, September 2, 2021
Medical Supplies, Health, Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Erasmus MC, Coronary artery disease, ICA, Muscle tissue, Degenerative disease, Diagnosis, Associate, Stenosis, FFR, National health insurance, Insurance, ICAS, Physician, Addition, Doctor of Philosophy, Moyamoya disease, JAMA, Randomized controlled trial, Heart, Dutch ship Admiraal Tjerk Hiddes De Vries, Fractional flow reserve, Intelligence, CTA, Silicon, Deep learning, Overalls, Â, Safety, Comparison, Patient, Erasmus, 3D, Principal, Chest pain, FACC, Ischemia, University Medical Center Utrecht, Perfusion, UMC, Driessen, Pharmaceutical industry, Medical imaging, the HeartFlow FFRct Analysis, HeartFlow, THE HEARTFLOW FFRCT ANALYSIS, HEARTFLOW

With the FUSION trial, we anticipate a 33% reduction in unnecessary ICAs which we believe will lead to cost savings for the overall healthcare system.

Key Points: 
  • With the FUSION trial, we anticipate a 33% reduction in unnecessary ICAs which we believe will lead to cost savings for the overall healthcare system.
  • The FUSION trial is planned to enroll 528 patients from six Dutch hospitals including Erasmus MC, UMCG, UMC Utrecht, the Admiraal de Ruyter Hospital in Goes, St Jansdal in Lelystad and Gelre hospitals Apeldoorn.
  • Patients whose CTA shows coronary artery disease will be randomized between the HeartFlow FFRct arm or the ICA arm.
  • Once the trial is complete, it is anticipated that the data will support insurance reimbursement in the Netherlands for the HeartFlow Analysis.

$ 489.4 Million growth in Global Fractional Flow Reserve Devices Market featuring Abbott Laboratories, ACIST Medical Systems Inc., B. Braun Melsungen AG and others | Technavio

Retrieved on: 
Tuesday, April 6, 2021
Occupational safety and health, Health, Articles, Medical specialties, COVID-19 pandemic, Pandemics, Fractional flow reserve, COVID-19

The fractional flow reserve devices market is expected to grow by USD 489.40 million during 2021-2025, according to Technavio.

Key Points: 
  • The fractional flow reserve devices market is expected to grow by USD 489.40 million during 2021-2025, according to Technavio.
  • The report offers a detailed analysis of the impact of the COVID-19 pandemic on the fractional flow reserve devices market in optimistic, probable, and pessimistic forecast scenarios.
  • The fractional flow reserve devices market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • Key Considerations for Market Forecast:
    Related Report on Healthcare Include:
    GlobalStructural Heart Disease Treatment Devices Market- Global structural heart disease treatment devices market is segmented byproduct (replacement devices and repair devices), end-user (hospitals and clinics and ASCs), and geography (North America, Europe, APAC, and ROW).